These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18431498)

  • 1. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.
    Tebas P; Henry WK; Matining R; Weng-Cherng D; Schmitz J; Valdez H; Jahed N; Myers L; Powderly WG; Katzenstein D
    PLoS One; 2008 Apr; 3(4):e2021. PubMed ID: 18431498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
    Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170.
    Skiest DJ; Krambrink A; Su Z; Robertson KR; Margolis DM;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):377-83. PubMed ID: 18931631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
    Phillips AN; Carr A; Neuhaus J; Visnegarwala F; Prineas R; Burman WJ; Williams I; Drummond F; Duprez D; Belloso WH; Goebel FD; Grund B; Hatzakis A; Vera J; Lundgren JD
    Antivir Ther; 2008; 13(2):177-87. PubMed ID: 18505169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE; Shen JM; Hahn B; Hallahan CW; Rehm CA; Thaker V; Wynne SM; Davey RT; Lane HC; Sereti I
    AIDS; 2006 Feb; 20(3):361-9. PubMed ID: 16439869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption.
    Seoane E; Resino S; Micheloud D; Moreno A; de Quiros JC; Lorente R; Rubio R; Gonzalez J; Pulido F; Arribas JR; Moreno S; Muñoz-Fernández M
    J Acquir Immune Defic Syndr; 2008 Aug; 48(4):455-9. PubMed ID: 18614926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers.
    Bonato M; Galli L; Passeri L; Longo V; Pavei G; Bossolasco S; Bertocchi C; Cernuschi M; Balconi G; Merati G; Lazzarin A; La Torre A; Cinque P
    BMC Infect Dis; 2017 Jan; 17(1):61. PubMed ID: 28077069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.
    Papasavvas E; Pistilli M; Reynolds G; Bucki R; Azzoni L; Chehimi J; Janmey PA; DiNubile MJ; Ondercin J; Kostman JR; Mounzer KC; Montaner LJ
    AIDS; 2009 Jan; 23(3):369-75. PubMed ID: 19114856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study.
    Olmo M; Saumoy M; Alonso-Villaverde C; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Curto J; Domingo P; Oteo JA; Vila A; Podzamczer D
    HIV Med; 2012 Sep; 13(8):488-98. PubMed ID: 22416676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy.
    Mokgalaboni K; Phoswa WN; Yates S; Lebelo SL; Madiba S; Modjadji P
    Int J Environ Res Public Health; 2023 Apr; 20(9):. PubMed ID: 37174188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.
    Stapleton JT; Chaloner K; Zhang J; Klinzman D; Souza IE; Xiang J; Landay A; Fahey J; Pollard R; Mitsuyasu R
    AIDS; 2009 Mar; 23(5):605-10. PubMed ID: 19194270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.